The Business Bytes
PRIYABRAT BISWAL
BHUBANESWAR, SEPT 23, 2022
Researchers at All India Institute of Medical Sciences (AIIMS) in New Delhi have found that Ayurvedic formulation BGR-34 – used in treating Type 2 diabetes – has a significant role in controlling obesity.
A team of doctors from country’s premier health research institute AIIMS- New Delhi has found that anti-diabetic ayurvedic drug BGR-34 is effective in cutting down obesity along with improving metabolism mechanisms of the patient afflicted with the chronic disease.
Led by Dr. Sudhir Chandra Sarangi, Additional Professor, Department of Pharmacology at AIIMS-New Delhi, the team reached this conclusion after a three-year study.
The study was aimed to investigate whether BGR-34 was effective on its own or along with other allopathic drugs; and if ‘yes’ then at what level. The results were encouraging. The researchers found that the herbal drug was enough not only in reduction of fasting blood sugar through modulation of hormonal profile along with a significant body weight reduction, but there were other benefits also.
The drug also modulates hormonal profile, lipid profile and triglyceride level while bringing down leptin mark which is effective in controlling fat. Triglyceride, in excess quantities, is harmful for the health as it is a bad cholesterol. Similarly, controlled lipid profile keeps heart diseases at bay while disturbance in hormonal profile can result in poor sleep, noted the authors about the research based on various health parameters.
In contrast, modulation of hormonal profile was found to be significant, resulting in increased insulin level.
The study initiated in March 2019 will soon be published in a research journal.
Comprising a range of ingredients from medicinal herbs like Giloy, Vijaysar, Daruharidra and Manjistha, BGR-34 has been developed by scientists from the Council of Scientific and Industrial Research’s labs — National Botanical Research Institute (NBRI) and Central Institute of Medicinal and Aromatic Plants (CIMAP), and is marketed by New Delhi-based AIMIL Pharmaceuticals.
Commenting on the development, AIMIL Pharmaceutical Executive Director Dr. Sanchit Sharma said: “Herbal-based Ayurvedic medicines are finding huge acceptance among people who are keen into taking preventive health measures in the backdrop of rising non communicable diseases due to lifestyle changes among others.”
“To cater to this increasing demand, the Government too has taken various measures to boost the availability of Ayurvedic products based on time-tested medicinal plants as immunity boosters. This will go a long way in achieving Prime Minister Narendra Modi’s vision of Healthy India,” he added.
It is pertinent to mention that another study published in the latest edition of Serbian Journal of Experimental and Clinical Research on Sciendo scientific platform has found that BGR-34 can help lower sugar level within three months and also exert a powerful antioxidant action to prevent complications of Type 2 diabetes, which is on the rise and accounts for 90 per cent of all instances of diabetes worldwide.
